1	
2	
3	
4	Potential risk polarization for acute myocardial infarction during the COVID-19
5	pandemic: Single-center experiences in Osaka, Japan
6	
7	
8	Masato Furui ^{1,2*} , Kenji Kawajiri ³ , Takeshi Yoshida ² , Bunpachi Kakii ² , Norikazu Oshiro ² , Mai
9	Asanuma ² , Hiroaki Nishioka ⁴ , Hideichi Wada ¹
10	
11	
12	¹ Cardiovascular Surgery Department, Fukuoka University Hospital, Nanakuma, Fukuoka,
13	Fukuoka, Japan
14	² Cardiovascular Surgery Department, Matsubara Tokushukai Hospital, Amamihigashi,
15	Matsubara, Osaka, Japan
16	³ Cardiology Department, Matsubara Tokushukai Hospital, Amamihigashi, Matsubara, Osaka,
17	Japan
18	⁴ Surgery Department, Matsubara Tokushukai Hospital, Amamihigashi, Matsubara, Osaka,
19	Japan
20	
21	Shape ! thill proprint to make a static infataction after the by Dev IDev Inpandombive used to guide clinical practice. 1

22

- 23 * Corresponding author:
- 24 E-mail: masatofurui@yahoo.co.jp (MF)

25

26 Abstract

This study compared the time course and outcomes of acute myocardial infarction. 27including mechanical complications and hospital mortality, before and after the coronavirus 28disease 2019 (COVID-19) pandemic at a regional core hospital in South Osaka, Japan. 29Moreover, it identified predictors for hospital mortality and mechanical complications. In total, 30503 patients who underwent emergency percutaneous coronary intervention between January 312011 and December 2021 at our institution were examined retrospectively. The time course of 32acute myocardial infarction, mechanical complications, and mortality rate before and after the 33 COVID-19 emergency declaration were compared. Overall, 426 patients with ST-segment 34elevation myocardial infarction and 77 patients with non-ST-segment elevation myocardial 35infarction were identified. For patients with ST-segment elevation myocardial infarction, the 36onset-to-door time was longer (181 vs. 156 min, P = 0.001) and mechanical complications 37were worse (7.8% vs. 2.6%, P = 0.025) after the emergency declaration of COVID-19 than 38before the pandemic. Age, low ejection fraction, out-of-hospital cardiac arrest, and mechanical 39complications were identified as independent risk factors for hospital mortality among patients 40with ST-segment elevation myocardial infarction, using multivariable 41analysis. Post-declaration, age, walk-ins, referrals, and intra-aortic balloon pump use were independent 4243predictors of mechanical complications among patients with ST-segment elevation myocardial infarction. Onset-to-door time and mechanical complication rate increased after the COVID-19 44declaration among patients with ST-segment elevation myocardial infarction. Arrival by 45walk-in and a referral that caused treatment delay were identified as independent risk factors 46for mechanical complication, in addition to age, use of intra-aortic balloon pump, and 47post-declaration of COVID-19. Therefore, the risks posed by the COVID-19 pandemic might 48have a polarization tendency resulting from the relief or worsening of cardiac symptoms. 49

51 Introduction

52	The coronavirus disease 2019 (COVID-19) pandemic has been in existence since
53	2020. The infection situation is not much different in Japan, and the nation has already
54	experienced the sixth wave of COVID-19. Common behavioral patterns have been adjusted to
55	reduce infection risk, and patients are being asked to avoid population-dense areas for the same
56	reason. Accordingly, a reduction in hospitalizations for acute myocardial infarction (AMI) has
57	been reported. [1-6] Although the impact of the COVID-19 pandemic on door-to-balloon time
58	and mechanical complications of AMI have been previously examined in other countries, such
59	reports are still scarce in Japan. [7–10]

A few studies on percutaneous coronary intervention (PCI) impact in Tokyo, Japan, have been reported; however, whether these are relevant to other regions is unknown due to the rural-urban emergency care disparity. [11,12] For example, South Osaka does not include a metropolitan area, being the second largest prefecture in Japan; therefore, accessibility to PCI-capable institutions will be different from that in Tokyo. [13,14] After the pandemic, studies considering consultation forms, such as walk-ins, direct arrival by emergency medical service (EMS), or referral transport from other non-PCI-capable facilities, are rare. [14]

Therefore, this study compared the time course and outcomes of AMI, including mechanical complications and in-hospital mortality, before and after the COVID-19 pandemic declaration at a regional core hospital in South Osaka, Japan. Moreover, this study examined whether differences in types of hospital visits were a predictor of the outcomes.

71

72 Materials and Methods

73 Study design and population

The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Matsubara Tokushukai Hospital (approval number: 22-01). The informed consent requirement from patients was waived due to the retrospective nature of this study. The corresponding author (Masato Furui) has full access to all data in this study and takes responsibility for data integrity and analysis.

79This study was a retrospective observational cohort study conducted on patients who underwent emergency PCI for AMI at the Matsubara Tokushukai Hospital in Osaka, Japan, 80 between January 2011 and December 2021. The medical records of 796 patients with acute 81 82 coronary syndrome (ACS) were reviewed, and data of 503 AMI patients were extracted after excluding those with recent myocardial infarction (MI) with an onset-to-door time >14 days 83 and unstable angina pectoris. The participants were classified into ST-segment elevation 84 myocardial infarction (STEMI) and non-STEMI (NSTEMI) groups. The Japanese government 85 declared a state of emergency on April 7, 2020, following the World Health Organization's 86 initial declaration of COVID-19 as a pandemic on March 11, 2020. [15,16] With this 87 88 emergency declaration as a borderline, the characteristics, time course, and outcomes were compared before and after the declaration to evaluate the impact of the COVID-19 pandemic 89 90 on both the STEMI and NSTEMI groups (Figure 1).

91

Fig 1. Flow chart illustrating the selection of the study participants. Abbreviations: ACS,
acute coronary syndrome; AMI, acute myocardial infarction; MI, myocardial infarction;
NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation
myocardial infarction; UAP, unstable angina pectoris.

96

97 **Definitions**

AMI was defined based on the fourth universal definition of MI, and ACS was defined 98 according to the Japanese Circulation Society guidelines. [17,18] Infarction was classified into 99 100 STEMI or NSTEMI, depending on the presence or absence of ST-segment elevation. Onset-to-door time and door-to-balloon time were defined as the time from symptom onset to 101hospital arrival and from hospital arrival to balloon dilation or thrombus aspiration, 102 respectively. [19] In the present study, renal dysfunction was defined as creatinine level >1.5 103mg/dL. Left ventricular ejection fraction (LVEF) was assessed using echocardiography. 104 Primary PCI was defined as urgent balloon angioplasty (with or without stenting) without 105106 employing fibrinolytic therapy to open the infarct-related artery.

107 The primary outcomes were onset-to-balloon time and in-hospital mortality. The 108 secondary outcome was the incidence of mechanical complications. Therefore, we compared 109 onset-to-door time, mechanical complications, and hospital mortality between patients before 110 and after the COVID-19 emergency declaration in Japan. Mechanical complications, including 111 cardiac rupture, ventricular septal perforation, and papillary muscle rupture, were assessed 112 using echocardiography. [20–22]

113

114 Statistical analysis

115 Categorical variables were expressed as numbers and proportions, whereas 116 continuous variables were presented as mean±standard deviation. Student's t-test, chi-squared 117 test, and Mann–Whitney U test were utilized for other statistical analyses. Multivariate logistic 118 regression analysis was performed for risk factors associated with hospital mortality and

119 mechanical complications in patients with STEMI. This analysis considered age, walk-ins, referrals, out-of-hospital cardiac arrest (OHCA), LVEF, single-vessel disease, anterior MI as a 120culprit, onset-to-door time, intra-aortic balloon pump (IABP) use, mechanical complications, 121122and post-COVID-19 declaration, as possible predictors. [7.22,23] The odds ratios (OR) and 95% confidence intervals (CI) were calculated. The number of patients who underwent 123venoarterial extracorporeal membrane oxygenation was few; therefore, it was not entered 124because we could not effectively analyze it. Moreover, NSTEMI analysis was not valid due to 125the small number. All statistical analyses were performed using JMP[®] version 9.0 (SAS 126127Institute Inc., Cary, NC), and differences were considered statistically significant at a *P*-value < 0.05. 128

129

130 **Results**

We extracted the data of 796 patients who required emergency PCI for ACS from 131medical records. Of these, 503 AMI patients were identified as participants in this study 132(Figure 1), of whom 426 and 77 patients were categorized into the STEMI and NSTEMI 133groups, respectively. Table 1 summarizes the basic characteristics, including the patients' 134background and pre-PCI examination findings before and after the COVID-19 declaration in 135each group. In the STEMI group, the number of patients with Killip classes $\mathbf{II}-\mathbf{IV}$ was 136significantly higher after the declaration than it was before the declaration (12.0% [42/349] vs.13721.3% [16/77], P=0.010). Although the prevalence of OHCA was not significantly different, it 138tended to be higher after the declaration (2.3% [8/349] vs. 6.5% [5/77], P=0.052). There were 139no significant differences in comorbidities, clinical presentation, and laboratory data before 140and after the declaration, except for Killip $\mathbb{II}-\mathbb{IV}$ classification in the STEMI group, as 141

142 previously described.

143

144 Table 1. Basic characteristics of AMI patients before and after the COVID-19

145 **declaration**.

Demographic	STEMI (n=426)			NSTEMI (n=77)		
S	Before	After	<i>P</i> -valu	Before	After	<i>P</i> -valu
n (%) or	declaration	declaration	e	declaration	declaratio	e
mean±SD	(n=349)	(n=77)		(n=62)	n	
					(n=15)	
Age (year)	67.7±12.6	68.7±11.9	0.514	67.3±12.7	71.6±11.4	0.152
Sex (male)	268	55 (71.4%)	0.139	46 (74.2%)	7 (46.7%)	0.842
	(76.8%)					
Body mass	24.0±4.0	23.7±4.0	0.642	23.7±3.9	22.3±3.5	0.703
index (kg/m ²)						
Comorbidities						
Hypertension	189	45 (58.4%)	0.494	35 (56.5%)	8 (53.3%)	0.075
	(54.2%)					
Diabetes	100	24 (31.2%)	0.660	15 (24.2%)	3 (20.0%)	0.737
mellitus	(28.7%)					
Dyslipidemia	121	30 (39.5%)	0.428	20 (32.3%)	7 (46.7%)	0.063
	(34.7%)					
Renal	161	27 (35.0%)	0.077	25 (40.3%)	3 (20.0%)	0.277
dysfunction	(46.1%)					
Dialysis	4 (1.1%)	2 (2.6%)	0.328	1 (1.6%)	0 (0%)	0.621

Cerebral	22 (6.3%)	5 (6.5%)	0.951	5 (8.1%)	3 (20.0%)	0.102
infarction						
COPD	3 (0.9%)	0 (0%)	0.414	0 (0%)	10 (66.7%)	0.041*
Prior PCI	36 (10.3%)	7 (9.1%)	0.747	9 (14.5%)	2 (13.3%)	0.187
Clinical						
presentation						
Killip	307	59 (78.7%)	0.010*	58 (93.5%)	10 (100%)	0.312
classification [†]	(88.0%)					
I - II						
III–IV	42 (12.0%)	16 (21.3%)	_	4 (6.5%)	0 (0%)	-
ОНСА	8 (2.3%)	5 (6.5%)	0.052	1 (1.6%)	1 (6.7%)	0.270
LVEF (%)	47±12	47±13	0.618	48±14	50±15	0.374
Laboratory						
data						
CPK [‡] (U/L)	453±771	398±622	0.562	529±881	255±234	0.256
Peak CPK	3198±2808	3428±3038	0.528	2073±2380	799±730	0.156
(U/L)						
CK-MB [‡] (U/L)	49±84	39±52	0.377	69±122	30±34	0.262
Peak CK-MB	297±302	274±216	0.531	189±199	80±75	0.248
(U/L)						
Troponin I [‡]	9378±3696	5491±1882	0.406	7905±2859	5855±1041	0.702

147 phosphokinase; LVEF, left ventricular ejection fraction; OHCA, out-of-hospital cardiac arrest;

146

148 PCI, percutaneous coronary intervention; and SD, standard deviation.

149 **P*<0.05.

[†]Killip classification after the declaration has a defect value of 2 in STEMI and 5 in NSTEMI.

151 [‡]Value at admission.

152

Table 2 shows consultation types, (such as walk-ins, arrival by EMS, and referrals,) the time course, and outcomes before and after the declaration in each group. In the STEMI group, there were fewer referred patients after the declaration than there were before the declaration. However, there was no significant difference in the door-to-balloon time before and after the declaration (109 ± 129 vs. 96 ± 54 min, P=0.420). Onset-to-door time (a primary outcome) in patients with STEMI was significantly longer after the COVID-19 declaration than it was before the declaration (156 ± 134 vs. 181 ± 145 min, P=0.001).

160

Table 2. Consultation type, time course, and outcomes in AMI patients before and after the declaration.

Demographics	STEMI (n=426)		NSTEMI (n=77)			
n (%) or	Before	After	<i>P</i> -valu	Before	After	<i>P</i> -valu
mean±SD	declaratio	declaratio	e	declaratio	declaratio	e
	n	n		n	n	
	(n=349)	(n=77)		(n=62)	(n=15)	

Consultation

type

Walk-in	50 (14.3%)	12 (16.0%)	0.733	9 (14.5%)	3 (20%)	0.599
EMS	296	64 (83.1%)	0.710	52 (83.9%)	12 (80.0%)	0.720
	(85.3%)					
In-hospital	2 (0.6%)	1 (1.3%)	0.491	1 (1.6%)	0 (0%)	0.621
patients						
Referral	94 (27.0%)	11 (14.3%)	0.019*	19 (30.7%)	2 (13.3%)	0.177
Time course						
Onset-to-door	156±134	181±145	0.001*	126±134	186±158	0.327
(min)						
Door-to-balloo	109±129	96±54	0.420	120±60	117±54	0.609
n (min)						
Culprit						
LMT	6 (1.7%)	1 (1.3%)	0.785	6 (9.7%)	0 (0%)	0.096
LAD	160	34 (44.2%)	-	19 (30.7%)	6 (40%)	_
	(45.9%)					
LCX	34 (9.7%)	9 (11.7%)	_	16 (25.8%)	8 (53.3%)	_
RCA	148	32 (41.6%)	-	19 (30.7%)	1 (6.7%)	_
	(42.4%)					
Diagonal	1 (0.3%)	1 (1.3%)	_	2 (3.2%)	0 (0%)	_
branch						
Mechanical						
Circulatory						
Support						
IABP	22 (6.3%)	7 (9.1%)	0.383	7 (11.3%)	0 (0%)	0.172

VA-ECMO	11 (3.2%)	4 (5.2%)	0.382	2 (3.2%)	0 (0%)	0.481
Outcomes						
Mechanical	9 (2.6%)	6 (7.8%)	0.025*	1 (1.6%)	1 (6.7%)	0.270
complications						
Cardiac	6 (1.7%)	3 (4.0%)	0.231	1 (1.6%)	0 (0%)	0.621
rupture						
Ventricular	2 (0.6%)	2 (2.7%)	0.100	0 (0%)	0 (0%)	_†
septal						
perforation						
Papillary	1 (0.3%)	1 (1.3%)	0.241	0 (0%)	1 (6.7%)	0.041*
muscle rupture						
In-hospital	36 (10.3%)	11 (14.3%)	0.299	5 (8.1%)	1 (6.7%)	0.856
mortality						

EMS, emergency medical service; IABP, intra-aortic balloon pump; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LMT, left main trunk; NSTEMI, non-ST-segment elevation myocardial infarction; RCA, right coronary artery; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction; and VA-ECMO, venoarterial extracorporeal membrane oxygenation.

168 **P*<0.05.

169 [†]The value is not valid.

170

Hospital mortality, another primary outcome, occurred in 11.0% (47/42 6) of patients
with STEMI and 7.8% (6/77) of patients with NSTEMI. Contrarily, mechanical complications,
a secondary outcome, occurred in 3.5% (15/426) of patients with STEMI patients and 2.6%

174(2/77) of patients with NSTEMI. The mechanical complication rate was significantly higher after the COVID-19 declaration than it was before the declaration (2.6% [9/349] vs. 7.8%175[6/77], P=0.025) in the STEMI group; however, there was no significant difference in hospital 176mortality (10.3% [36/349] vs. 14.3% [11/77], P=0.299). 177Table 3 presents the results of the multivariate analysis for the primary outcomes. Age 178(1-year increase: OR 1.087, 95% CI 1.045–1.135, $P \le 0.0001$), OHCA (OR 61.883, 95% CI 1799.726–595.506, P<0.0001), LVEF (1% increase: OR 0.943, 95% CI 0.911–0.975, P=0.0004), 180IABP use (OR 10.523, 95% CI 3.544–33.544, $P \le 0.0001$), and mechanical complications (OR 181 10.724, 95% CI 2.233-57.236, P=0.003) were established as independent predictors of 182hospital mortality. Table 4 presents the results of the multivariate analysis for the secondary 183outcome. Age (1-year increase: OR 1.115, 95% CI 1.037–1.221, P=0.0019), walk-in visits (OR 18414.695, 95% CI 3.265-80.468, P=0.0005), referral visits (OR 4.854, 95% CI 1.050-25.003, 185P=0.043), IABP use (OR 29.094, 95% CI 4.209–255.552, P=0.0008), and post-COVID-19 186declaration (OR 5.006, 95% CI 1.131-22.443, P=0.035) were identified as independent 187 predictors of mechanical complications. 188

189

190 Table 3. Multivariate logistic regression analysis of risk factors for STEMI.

Dependent variable: hospital mortality						
	Odds ratio	95% CI	<i>P</i> -value			
Age (per year)	1.087	1.045-1.135	<0.0001*			
Walk-in	2.000	0.527-10.829	0.332			

Referral	0.744	0.289–1.999	0.550
ОНСА	61.883	9.726–595.506	<0.0004*
LVEF (1% increase)	0.943	0.911-0.975	0.0019*
Single-vessel disease	1.009	0.420–2.418	0.9845
Culprit: anterior (vs. others)	1.584	0.661–3.929	0.3042
Onset-to-door time (per min)	1.001	0.998–1.005	0.5175
IABP	10.523	3.544-33.544	<0.0001*
Mechanical complications	10.724	2.233-57.236	0.0030*
Post-declaration (vs.	1.030	0.293–3.129	0.9603
pre-declaration)			

CI, confidence interval; IABP, intra-aortic balloon pump; LVEF: left ventricular ejection
fraction; OHCA, out-of-hospital cardiac arrest; and STEMI, ST-segment elevation myocardial
infarction.

194 **P*<0.05.

195

196 **Table 4. Multivariate logistic regression analysis of risk factors for STEMI.**

Dependent variable: mechanical complications

-	-		
	Odds ratio	95% CI	<i>P</i> -value
Age (per year)	1.115	1.037–1.221	0.0019*
Walk-in	14.695	3.265-80.468	0.0005*
Referral	4.854	1.050-25.003	0.0432*

LVEF (1% increase)	0.971	0.915-1.030	0.276
Single-vessel disease	2.478	0.619–11.348	0.202
Culprit: anterior (vs. others)	3.330	0.792–16.673	0.102
Onset-to-door time (per min)	1.003	0.999–1.006	0.085
IABP	29.094	4.209–255.552	0.0008*
Post-declaration	5.006	1.131–22.443	0.035*
· · · · ·			

(vs. pre-declaration)

CI, confidence interval; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection
fraction; and STEMI, ST-segment elevation myocardial infarction.

199 **P*<0.05.

200

Table 5 shows the association of walk-ins and referrals with the time course after the declaration in patients with STEMI. Regarding arrival by walk-in, both onset-to-door and door-to-balloon times were significantly extended in patients with walk-in arrivals, compared with those from non-walk-in arrivals (175 vs. 127 min, P=0.015 and 150 vs. 95 min, P=0.038). Conversely, referral patients had a significantly longer onset-to-door time (164 vs. 124 min, P=0.016) and shorter door-to-balloon time than non-referral patients (87 vs. 113 min, P=0.009).

208

Table 5. The association of walk-ins and referrals with time course after COVID-19
declaration in the STEMI group.

Time course	Walk-in	Non-walk-in	<i>P</i> -value	Referral	Non-referral	<i>P</i> -value
mean (range)	(n=65)	(n=31)		(n=105)	(n=321)	

Onset-to-door	175	(12–	127 (6–1080)	0.015*	164 (6-	124 (6-840)	0.016*
time (min)	840)				1080)		
Door-to-balloon	150	(42–	95 (29–437)	0.038*	87 (29–	113 (38–	0.009*
time (min)	1337)				199)	1337)	

211 STEMI indicates ST-segment elevation myocardial infarction.

212 **P*<0.05.

213

214 **Discussion**

Several studies have reported the impact of the COVID-19 pandemic on AMI in 215Tokyo. [3,7] However, our hospital's secondary medical service area in South Osaka is distinct 216from that in Tokyo and has an unevenly distributed population, similar to hospitals, especially 217PCI-capable facilities. [13,24,25] Moreover, arrival by walk-in or referral as risk factors for 218AMI have rarely been discussed following the COVID-19 pandemic. Therefore, our study 219220investigated the influence of walk-ins and referrals on mechanical complications and hospital 221mortality to address this and compare time course and outcomes before and after the COVID-19 pandemic in STEMI and NSTEMI groups. We established that onset-to-door time 222223was prolonged and mechanical complications developed more frequently in STEMI patients after the COVID-19 declaration, with no significant difference between both groups. These 224findings suggest that, in addition to post-COVID-19 declaration, walk-ins and referrals were 225risk factors for mechanical complications. 226

Regarding risk factors for hospital mortality, it was reported that patients with lower LVEF have higher mortality rates and develop heart failure easily. [26,27] Once mechanical complications occur, they can fatally affect patients' hemodynamics. Although various

operative procedures and strategies in surgery timing have been devised, operative mortality
 remains high. [21,22,28] Therefore, investigating the risk factors and preventing subsequent
 complications may be important in reducing associated mortality.

Several risk factors for mechanical complications are known; previous studies have shown that established mechanical complication risk factors include age, female sex, anterior MI, de novo MI, and single-vessel disease. However, the analysis conducted in this study did not identify single-vessel disease and anterior MI as mechanical complication risk factors. [21,22] Moreover, once mechanical complications occur, patients often experience cardiogenic shock, thus requiring IABP use, which may naturally become a risk factor.

Considering previous findings, the identification of walk-ins and referrals as risk 239factors for mechanical complications are unique points in the present study. Walk-in patients 240241often have mild symptoms, making this seem contradictory. However, in some cases with mild symptom presentation, patients' hearts can suffer from unnoticed load until AMI diagnosis, 242243even after visiting the hospital because of unrestricted patient mobility or activity. Failure to limit this activity may become a mechanical complication risk. Thus, the time course for 244walk-in patients is distinct from that for patients transported by ambulance. Patients who notify 245the EMS are likely to immediately undergo consultation and check-ups by emergency doctors 246who begin monitoring as soon as the patient arrives at the hospital. Useful information by 247248rescue crews generally aids in smooth AMI diagnosis. Conversely, walk-in patients have to wait longer for consultation or check-ups. Therefore, there may be a pronounced time lag from 249their arrival to diagnosis or PCI, compared with that of patients who notify EMS. 250

Referred patients were reported to have a prolonged onset-to-door time because they came from a nearby clinic or were transferred from non-PCI-capable facilities. [14,19] Previous studies reported that the time interval from an AMI onset to ventricular septal

perforation manifestation had a bimodal distribution; therefore, a longer ischemic time can 254become a risk factor for mechanical complications due to interactions with unknown factors. 255[10,22] In contrast, there was a significantly shorter door-to-balloon time in referred patients 256with STEMI after the pandemic declaration. Although we could not specify the reason, 257preparing for PCI in advance by referral request and an improved acceptance system by the 258regional cooperation office might achieve a shorter door-to-balloon time. In any case, because 259260a referral is indispensable due to the surrounding non-PCI-capable facilities, we suggest that an effective EMS system and crew education on carrying suspected patients to PCI-capable 261262facilities is important. [11,13,14]

In the STEMI group, OHCA rates tended to be higher after the declaration than it was 263before, although this failed to reach statistical significance. Given the potential for a higher 264OHCA rate and risk factors for mechanical complications, such as walk-ins and referrals, AMI 265risk polarization may have emerged on the clinical scene during the COVID-19 pandemic. 266Although rare, spontaneous reperfusion occurs in 7–30% of patients with STEMI, as stated in 267previous studies. [29,30] In addition, patients who follow stay-at-home orders and initially 268tolerate or adapt to their symptoms may likely experience spontaneous reperfusion. Walk-in 269270patients with apparently mild symptoms or referred patients with STEMI may be at risk of mechanical complications, which were identified in the present study as mortality risk in 271272STEMI after the COVID-19 pandemic. Therefore, care should be taken regarding walk-in or referral patients suspected of STEMI. 273

274 Conversely, more severe symptoms can result in patients notifying EMS; however, 275 their situation can become critical due to delays that may lead to OHCA during transport to 276 PCI-capable facilities. The fear of contracting COVID-19 may have led to patient hesitation to 277 visit hospitals, resulting in risk polarization (Figure 2). Timely arrival to PCI-capable facilities

278 without hesitation is necessary for patients at risk of AMI.

279

Fig 2. Polarization tendency of potential risks occurring from the patients' psychology and possible time course after the COVID-19 pandemic. Abbreviations: EMS, emergency medical service; OHCA, out-of-hospital cardiac arrest.

283

The first limitation of this study is its retrospective observational design coupled with 284limited sample size from a single center. Our hospital covers only one of the areas in South 285Osaka. Thus, our data may not accurately represent Osaka as a whole because of emergency 286care or PCI volume disparity. [11–13] Second, additional data, encompassing EMS calls, 287transfer-to-door time, or COVID-19 examination waiting time, may be desirable in future 288studies to support the initial findings outlined in this study. Finally, the number of patients who 289290died at home or during transport to our hospital was unknown and were excluded from the study population; therefore, OHCA and AMI prevalence rates may have been underestimated. 291Future research including these data will be required to further evaluate AMI-related mortality 292293risk or mechanical complications during the COVID-19 pandemic.

294

295 Conclusion

The onset-to-door time was prolonged and mechanical complications developed more frequently in patients with STEMI after the COVID-19 pandemic declaration than it did before. Age, low LVEF, OHCA, IABP use, and mechanical complications were established as independent risk factors for hospital mortality in patients with STEMI. Additionally, age,

300 walk-ins, referrals, and IABP use were identified as independent predictors of mechanical 301 complications in those with STEMI. Arrival by walk-in or referral, in patients with mild 302 symptoms, influenced the outcomes of patients with AMI. Therefore, the risks posed by the 303 COVID-19 pandemic might have a polarization tendency resulting from the relief or 304 worsening of cardiac symptoms.

305

306 Acknowledgments

307 We would like to thank Editage for English editing services.

308

309 **References**

- Bhatt AS, Moscone A, McElrath EE, Varshney AS, Claggett BL, Bhatt DL, et al.
 Fewer hospitalizations for acute cardiovascular conditions during the COVID-19
 pandemic. J Am Coll Cardiol. 2020; 76: 280-288.
- Toscano O, Cosentino N, Campodonico J, Bartorelli AL, Marenzi G. Acute myocardial
 infarction during the COVID-19 pandemic: an update on clinical characteristics and
 outcomes. Front Cardiovasc Med. 2021; 8: 648290.
- 316
 3. Arai R, Fukamachi D, Ebuchi Y, Migita S, Morikawa T, Monden M, et al. Impact of
 the COVID-19 outbreak on hospitalizations and outcomes in patients with acute
 myocardial infarction in a Japanese single center. Heart Vessels. 2021; 36: 1474-1483.
- Morishita T, Takada D, Shin JH, Higuchi T, Kunisawa S, Imanaka Y. Trends, treatment
 approaches, and in-hospital mortality for acute coronary syndrome in Japan during the
 coronavirus disease 2019 pandemic. J Atheroscler Thromb. 2022; 29: 597-607.

- 5. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, et al.
 Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19
 era. Eur Heart J. 2020; 41: 2083-2088.
- Erol MK, Kayıkçıoğlu M, Kılıçkap M, Güler A, Yıldırım A, Kahraman F, et al.
 Treatment delays and in-hospital outcomes in acute myocardial infarction during the
 COVID-19 pandemic: a nationwide study. Anatol J Cardiol. 2020; 24: 334-342.
- Watanabe Y, Miyachi H, Mozawa K, Yamada K, Oka E, Shiomura R, et al. Impact of
 the COVID-19 pandemic on ST-elevation myocardial infarction from a single-center
 experience in Tokyo. Intern Med. 2021; 60: 3693-3700.
- Kitahara S, Fujino M, Honda S, Asaumi Y, Kataoka Y, Otsuka F, et al. COVID-19
 pandemic is associated with mechanical complications in patients with ST-elevation
 myocardial infarction. Open Heart. 2021; 8: e001497.
- 9. Kobayashi S, Sakakura K, Jinnouchi H, Taniguchi Y, Tsukui T, Watanabe Y, et al.
 Comparison of door-to-balloon time and in-hospital outcomes in patients with
 ST-elevation myocardial infarction between before versus after COVID-19
 pandemic. Cardiovasc Interv Ther. 2022; 37: 641-650.
- 10. Fardman A, Zahger D, Orvin K, Oren D, Kofman N, Mohsen J, et al. Acute myocardial
 infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital
 outcomes- A multicenter registry. PLoS ONE 2021; 16: e0253524
- 341 11. Masuda J, Kishi M, Kumagai N, Yamazaki T, Sakata K, Higuma T, et al. Rural-urban
 342 disparity in emergency care for acute myocardial infarction in Japan. Circ J. 2018; 82:
 343 1666-1674.
- 12. Matsuzawa Y, Konishi M, Nakai M, Saigusa Y, Taguri M, Gohbara M, et al.

- 345 In-hospital mortality in acute myocardial infarction according to population density 346 and primary angioplasty procedures volume. Circ J. 2020; 84: 1140-1146.
- 347 13. Kinoshita N, Imai K, Kinjo K, Naka M. Longitudinal study of acute myocardial
 348 infarction in the southeast Osaka district from 1988 to 2002. Circ J. 2005; 69:
 349 1170-1175.
- 14. Higuma T, Hanada H, Okumura K. Direct transfer, shorter onset-to-balloon time, and
 better clinical outcome in ST-segment elevation myocardial infarction. Circ J.
 2015; 79: 1897-1899.
- 353 15. Mahase E. COVID-19: WHO declares pandemic because of "alarming levels" of
 354 spread, severity, and inaction. BMJ 2020; 368: m1036.
- 16. Looi MK. COVID-19: Japan declares state of emergency as Tokyo cases soar. BMJ
 2020; 369: m1447.
- 17. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth
 Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018; 72:
 2231-2264.
- 18. Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018
 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019; 83:
 1085-1196.
- 363 19. Tsukui T, Sakakura K, Taniguchi Y, Yamamoto K, Seguchi M, Wada H, et al.
 364 Association between the door-to-balloon time and mid-term clinical outcomes in
 365 patients with ST-segment elevation myocardial infarction. Intern Med. 2020; 59:
 366 1597-1603.
- 367 20. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, et al.

368	Cardiogenic shock complicating acute myocardial infarctionetiologies, management
369	and outcome: a report from the SHOCK Trial Registry. SHould we emergently
370	revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol.
371	2000; 36: 1063-1070.
372	21. Honda S, Asaumi Y, Yamane T, Nagai T, Miyagi T, Noguchi T, et al. Trends in the
373	clinical and pathological characteristics of cardiac rupture in patients with acute
374	myocardial infarction over 35 years. J Am Heart Assoc. 2014; 3: e000984.
375	22. Damluji AA, van Diepen S, Katz JN, Menon V, Tamis-Holland JE, Bakitas M, et al.
376	Mechanical complications of acute myocardial infarction: a scientific statement from
377	the American Heart Association. Circulation 2021; 144: e16-e35.
378	23. Novak M, Hlinomaz O, Groch L, Rezek M, Semenka J, Sikora J, et al. Ventricular
379	septal rupture - a critical condition as a complication of acute myocardial infarction. J
380	Crit Care Med (Targu Mures). 2015; 1: 162-166.
381	24. Osaka prefectural government-estimated population (monthly report). Available at:
382	https://www.pref.osaka.lg.jp/toukei/jinkou/jinkou-xlslist.html. Accessed March 27,
383	2022.
384	25. Japan medical analysis platform by the Japan Medical Association. Available at:
385	https://jmap.jp/cities/detail/pref/27. Accessed March 27, 2022.
386	26. Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a
387	review. JAMA 2020; 324: 488-504.
388	27. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of
389	empagliflozin on the clinical stability of patients with heart failure and a reduced
390	ejection fraction: the EMPEROR-Reduced Trial. Circulation 2021; 143: 326-336.

391	28. Furui M, Sakurai Y, Kakii B, Asanuma M, Nishioka H, Yoshida T. Benefits and risks
392	of delayed surgery for ventricular septal rupture after acute myocardial infarction. Int
393	Heart J 2022; 63: 433-440.
394	29. Uriel N, Moravsky G, Blatt A, Tourovski A, Gabara Z, Inna Y, et al. Acute myocardial
395	infarction with spontaneous reperfusion: clinical characteristics and optimal timing for
396	revascularization. Isr Med Assoc J. 2007; 9: 243-246.
397	30. Li X, Li B, Gao J, Wang Y, Xue S, Jiang D, et al. Influence of angiographic

- 398 spontaneous coronary reperfusion on long-term prognosis in patients with ST-segment
- elevation myocardial infarction. Oncotarget 2017; 8: 79767-79774.



Figure 1



Figure 2